AM 9747
Alternative Names: AM-9747Latest Information Update: 20 Jun 2023
At a glance
- Originator Amgen
- Class Antineoplastics; Small molecules
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 14 Apr 2023 Preclinical trials in Haematological malignancies in USA (unspecified route)
- 14 Apr 2023 Preclinical trials in Solid tumours in USA (unspecified route), prior to April 2023
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in Solid tumour presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)